Researchers developed a quick and affordable whole-blood assay to detect autoantibodies against type I IFNs, enabling rapid diagnostics for immune disorders. This new method has potential clinical impact by addressing key limitations of current tests.
How Q1 2024 Could Be Vital for Cybin’s FDA Milestones
The Dales Report is here with a psychedelics exclusive podcast. In this episode of Trade To Black with CEO Doug Drysdale, we catch up with